DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Motzer R, Nosov D, Eisen T et al.
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.
In: J Clin Oncol.
2012
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.